Multi-drug resistant tuberculous spondylitis: A review of the literature
While tuberculous vertebral osteomyelitis is an ancient scourge, multi-drug resistant-tuberculosis (MDR-TB) is a modern major public health concern. The objective of this study was to review and summarize the data available on MDR-TB spondylitis. An extensive search of the PubMed database was conduc...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2016-01-01
|
| Series: | Annals of Thoracic Medicine |
| Subjects: | |
| Online Access: | http://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2016;volume=11;issue=4;spage=233;epage=236;aulast=Kizilbash |
| _version_ | 1819117995694227456 |
|---|---|
| author | Quratulain Fatima Kizilbash Barbara Joyce Seaworth |
| author_facet | Quratulain Fatima Kizilbash Barbara Joyce Seaworth |
| author_sort | Quratulain Fatima Kizilbash |
| collection | DOAJ |
| description | While tuberculous vertebral osteomyelitis is an ancient scourge, multi-drug resistant-tuberculosis (MDR-TB) is a modern major public health concern. The objective of this study was to review and summarize the data available on MDR-TB spondylitis. An extensive search of the PubMed database was conducted for articles in English relevant to MDR-TB spondylitis by December 2015. Tuberculous spondylitis accounts for 0.5–1% of all TB cases, and it is estimated that there are probably 5000 MDR-TB spondylitis cases each year worldwide. The diagnosis of MDR-TB spondylitis requires a high index of suspicion based on epidemiologic, clinical, and radiologic features. Cultures and susceptibility testing remain the gold standard for the diagnosis of MDR-TB, but this can take several weeks to obtain. Medical treatment is the mainstay of therapy, and ideally, it should be based on drug susceptibility testing. If empiric treatment is necessary, it should be based on drug exposure history, contact history, epidemiology, and local drug resistance data, if available. The total duration of treatment should not be <18–24 months. Clinical, radiographic, and if possible, bacteriologic improvement should be used to assess the treatment success. Surgery should be reserved for neurologic deterioration, significant kyphosis, spinal instability, severe pain, and failure of medical management. |
| first_indexed | 2024-12-22T05:41:50Z |
| format | Article |
| id | doaj.art-5c7a18b2a7dc4c92889751161f0ce576 |
| institution | Directory Open Access Journal |
| issn | 1817-1737 1998-3557 |
| language | English |
| last_indexed | 2024-12-22T05:41:50Z |
| publishDate | 2016-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Annals of Thoracic Medicine |
| spelling | doaj.art-5c7a18b2a7dc4c92889751161f0ce5762022-12-21T18:37:10ZengWolters Kluwer Medknow PublicationsAnnals of Thoracic Medicine1817-17371998-35572016-01-0111423323610.4103/1817-1737.191867Multi-drug resistant tuberculous spondylitis: A review of the literatureQuratulain Fatima KizilbashBarbara Joyce SeaworthWhile tuberculous vertebral osteomyelitis is an ancient scourge, multi-drug resistant-tuberculosis (MDR-TB) is a modern major public health concern. The objective of this study was to review and summarize the data available on MDR-TB spondylitis. An extensive search of the PubMed database was conducted for articles in English relevant to MDR-TB spondylitis by December 2015. Tuberculous spondylitis accounts for 0.5–1% of all TB cases, and it is estimated that there are probably 5000 MDR-TB spondylitis cases each year worldwide. The diagnosis of MDR-TB spondylitis requires a high index of suspicion based on epidemiologic, clinical, and radiologic features. Cultures and susceptibility testing remain the gold standard for the diagnosis of MDR-TB, but this can take several weeks to obtain. Medical treatment is the mainstay of therapy, and ideally, it should be based on drug susceptibility testing. If empiric treatment is necessary, it should be based on drug exposure history, contact history, epidemiology, and local drug resistance data, if available. The total duration of treatment should not be <18–24 months. Clinical, radiographic, and if possible, bacteriologic improvement should be used to assess the treatment success. Surgery should be reserved for neurologic deterioration, significant kyphosis, spinal instability, severe pain, and failure of medical management.http://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2016;volume=11;issue=4;spage=233;epage=236;aulast=KizilbashDiagnosismedicalmulti-drug resistant tuberculosisspinesurgical |
| spellingShingle | Quratulain Fatima Kizilbash Barbara Joyce Seaworth Multi-drug resistant tuberculous spondylitis: A review of the literature Annals of Thoracic Medicine Diagnosis medical multi-drug resistant tuberculosis spine surgical |
| title | Multi-drug resistant tuberculous spondylitis: A review of the literature |
| title_full | Multi-drug resistant tuberculous spondylitis: A review of the literature |
| title_fullStr | Multi-drug resistant tuberculous spondylitis: A review of the literature |
| title_full_unstemmed | Multi-drug resistant tuberculous spondylitis: A review of the literature |
| title_short | Multi-drug resistant tuberculous spondylitis: A review of the literature |
| title_sort | multi drug resistant tuberculous spondylitis a review of the literature |
| topic | Diagnosis medical multi-drug resistant tuberculosis spine surgical |
| url | http://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2016;volume=11;issue=4;spage=233;epage=236;aulast=Kizilbash |
| work_keys_str_mv | AT quratulainfatimakizilbash multidrugresistanttuberculousspondylitisareviewoftheliterature AT barbarajoyceseaworth multidrugresistanttuberculousspondylitisareviewoftheliterature |